calprotectin Archives - Page 3 of 8 - Buhlmann Diagnostics Corp

Tag: calprotectin

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® ELISA Calprotectin Test

BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 12, 2018: BÜHLMANN Laboratories AG, is proud to announce it has received United States Food and
Continue Reading

BUHLMANN – LabSense News Spring 2018 Edition

In this “Summer Edition” we are pleased to share the launch of the of Quantum Blue® Adalimumab assay as well as announce some recent enhancements to the Quantum Blue® Infliximab assay. We also make mention of the upcoming meetings…

Continue Reading

IBDoc and Me

Health Canada Licence: 98903, Device class: 3  IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc®  since last October and is trying this new tool to monitor his Crohn’s Disease.  He has been documenting his experiences in a blog to share his
Continue Reading

Join Us at CSCC 2018 in Ottowa!

Canadian Society for Clinical Chemists (CSCC) 2018 BUHLMANN Diagnostics Corp  Booth: #410 June 03 - 06, 2018 | Fairmont Château Laurier Hotel. | Ottawa, ON Learn More Come by our booth to get an update on our Calprotectin,Therapeutic Drug Monitoring, Chemistry, Neuroimmunology, and Cellular Allergy portfolios Calprotectin and TDM: IBDoc®, the ONLY in-vitro diagnostic POC and home testing
Continue Reading

BUHLMANN LabSense News Winter 2018 Edition

BUHLMANN Diagnostics Corp is proud to release the sixth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. Check Out LabSense News Today! What's New Introducing BAT in Food Allergy Webinar recording and eBook by Dr. Alexandra Santos as well as two new IBDoc®  Posters
Continue Reading

Connect with BUHLMANN at CDDW 2018 in Toronto

Canadian Digestive Diseases Week (CDDW) 2018 BUHLMANN Diagnostics Corp  Booth: #135 Feb 09 - 11, 2018 | The Fairmont Royal York | Toronto, ON Learn More Come by our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the ONLY in-vitro diagnostic POC and home testing device to measure the inflammatory marker,
Continue Reading

Evaluation of the BÜHLMANN fCAL® turbo Test at City Hospital Triemli in Zurich

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 French Version INTERVIEW WITH ANITA GRÜNAUER AND PREDRAG NESIC, City Hospital Triemli, Zurich Mrs. Grünauer and Mr. Nesic, several months ago you decided to implement the BÜHLMANN fCAL® turbo on your Roche cobas® c501 system. Can
Continue Reading

BUHLMANN LabSense News: Fall 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the fifth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. You won’t want to miss some interesting highlights for the Flow CAST® assay including interesting videos, ebooks and more in this edition! Check Out LabSense News Today! VIEW
Continue Reading

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis

BÜHLMANN fCAL® ELISA: Kristensen, V., A. Roseth, et al.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.  Gastroenterology Research and Practice; Volume 2017 (2017), Article ID 2098293, 5 pages.  DOI: 10.1155/2017/2098293. Highlights from this Publication “Conclusions. Fecal calprotectin <250 μg/g after medical treatment for active ulcerative colitis is a reliable marker of endoscopic
Continue Reading